IPP Bureau
Alembic Pharmaceuticals receives USFDA final approval for Divalproex Sodium Delayed-Release Capsules
By IPP Bureau - December 22, 2024
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
Briefs: Laurus Bio and Cupid
By IPP Bureau - December 22, 2024
Laurus Labs informs that Eight Roads Ventures and F-Prime Capital (Investors) have together invested Rs. 120 crores in Laurus Bio
Shilpa Medicare’s Unit VII, Nacharam, Hyderabad receives GMP certificate from EMA, Austria
By IPP Bureau - December 22, 2024
The company has received the GMP Certification after successful closure of the inspection
CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA
By IPP Bureau - December 22, 2024
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Reliance Digital Health Ltd to acquire 45% in Health Alliance Group
By IPP Bureau - December 22, 2024
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
Briefs: Gandhar Oil Refinery India, FDC and Apitoria Pharma
By IPP Bureau - December 22, 2024
FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets
Lupin Digital Health partners with Medicover Hospitals for post discharge cardiac care
By IPP Bureau - December 22, 2024
Lonza expands capsule manufacturing capacity in India and China
By IPP Bureau - December 21, 2024
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
ANVISA inspection received from Brazil Health Regulatory Agency at Wanbury Tanuku facility
By IPP Bureau - December 21, 2024
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC
By IPP Bureau - December 21, 2024
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Merck closes license agreement for LM-299
By IPP Bureau - December 21, 2024
Merck will record a pre-tax charge relating to the upfront payment of $588 million
India is the fourth largest medical devices market in Asia: Anupriya Patel
By IPP Bureau - December 20, 2024
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Zydus receives final approval from USFDA for Lidocaine and Prilocaine Cream USP
By IPP Bureau - December 20, 2024
Lidocaine and Prilocaine cream had annual sales of US $22.05 million in the United States (IQVIA MAT October 2024)
Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’
By IPP Bureau - December 20, 2024
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
